Mon, Mar 2, 2015, 3:07 AM EST - U.S. Markets open in 6 hrs 23 mins


% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • docihi docihi Sep 4, 2012 11:15 AM Flag

    i have written about this at least 20 times

    i have laid out the gem/abraxane, gem/vis, gem/abraxane/vis (triple) studies, and that the estimated primary completion dates for the gem/abraxane (phase iii) and the triple (phase ii) are both 12/12. i have pointed out that dr. von hoff hasn't mentioned the triple su2c study since 2010, but has repeatedly reported on his gem/abraxane study, including his latest su2c video talking about the phase ii results from the gem/abraxane study which showed 48% first year (now changed to 50%) and good two year survival and up to 2 and 4 years. i have stated that he probably quit talking about the triple trial because of restrictions placed by gen/roche. in addition, kimmel is still for the triple trial.

    i expect dr von hoff will again talk about the gem/abraxane phii results and add some phase iii data to his su2c presesntation on the 9/7 tv show. he may also mention other promising pancreatic trials. in my opinion, he will not mention anything about the triple trial at su2c show unless gen/roche wants him to. i have also said that, from a scientific standpoint the triple combination makes sense and that both trials are von hoff trials. when the triple phii data are released they may showed better results that the gem/abraxane phii results, or not.

3.08-0.07(-2.22%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.